ramosetron + tropisetron + dexamethasone

This is a combination of three drugs—ramosetron, tropisetron, and dexamethasone—used primarily for the prevention and treatment of nausea and vomiting, particularly in settings such as chemotherapy-induced nausea and vomiting (CINV) or postoperative nausea and vomiting (PONV). - **Ramosetron** is a selective serotonin 5-HT3 receptor antagonist with high affinity and long duration of action. It blocks serotonin receptors both centrally in the chemoreceptor trigger zone and peripherally on vagal nerve terminals in the gastrointestinal tract, thereby preventing emesis[4][5][7]. - **Tropisetron** is also a selective 5-HT3 receptor antagonist that inhibits serotonin-mediated emetic signals[1][6][8]. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory properties; its antiemetic mechanism may involve inhibition of prostaglandin synthesis or reduction of inflammation around the vomiting center[1][2][4]. The rationale for combining these agents lies in their complementary mechanisms. The dual blockade of 5-HT3 receptors by ramosetron and tropisetron provides robust inhibition of serotonergic pathways involved in emesis, while dexamethasone adds further efficacy through non-serotonergic mechanisms. Clinical studies have shown that combinations involving two out of these three drugs (e.g., ramosetron + dexamethasone or tropisetron + dexamethasone) are more effective than monotherapy for preventing PONV or CINV[1][2][4][6].